Amphastar Pharma (AMPH) Tops Q4 EPS by 12c, Slight Miss on Revenues

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.10, $0.12 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $60.4 million versus the consensus estimate of $60.62 million.

Fourth Quarter Highlights

• Net revenues of $60.4 million for the fourth quarter
• GAAP net income of $1.5 million, or $0.03 per diluted share, for the fourth quarter
• Adjusted non-GAAP net income of $4.8 million, or $0.10 per diluted share, for the fourth quarter

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• After-Hours Stock Movers: FDX, CBRS, NKE
• JPMorgan Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Underweight